Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report-Reference-Cited by-同舟云学术

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report

Published:2022-04 Issue: Volume:Volume 15 Page:323-328
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Zhao Yingchao,Jiang Yao^ORCID

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference32 articles.

1. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference

2. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010

3. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis

4. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies

5. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies—Therapeutic Vulnerabilities in Treatment-Resistant Subtypes;Cancers;2024-09-03

2. Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series;Gynecologic Oncology Reports;2024-06

3. Promising Remission with Reduced Bevacizumab and Pembrolizumab Dosage in a Patient with AT-rich Interaction Domain 1A Mutated Ovarian Clear-cell Carcinoma Refractory to Chemotherapy;Journal of Cancer Research and Practice;2024-01

4. Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy;Anticancer Research;2023-07-26

5. Carboplatin/paclitaxel;Reactions Weekly;2022-05